Skip to main content
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. — Investor Relations & Filings

Ticker · KYMR ISIN · US5015751044 US Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Filings indexed 527 across all filing types
Latest filing 2026-04-30 Interim / Quarterly Rep…
Country US United States of America
Listing US KYMR

About Kymera Therapeutics, Inc.

https://www.kymeratx.com/

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the field of targeted protein degradation (TPD) to develop novel small molecule medicines. The company's proprietary drug discovery engine, Pegasus™, enables the creation of first-in-class therapeutics designed to selectively degrade disease-causing proteins, thereby addressing the root cause of illness. Kymera's pipeline is focused on developing oral medicines for diseases with high unmet medical needs, particularly in the areas of immunology, inflammation, and oncology. The company aims to redefine treatment paradigms by targeting proteins that have been previously considered undruggable.

Recent filings

Filing Released Lang Actions
10-Q - Kymera Therapeutics, Inc. (0001815442) (Filer)
Interim / Quarterly Report
2026-04-30 English
8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)
Regulatory Filings
2026-04-30 English
8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)
Regulatory Filings
2026-03-27 English
SCHEDULE 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)
Major Shareholding Notification
2026-03-27 English
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
Director's Dealing
2026-03-25 English
144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
Regulatory Filings
2026-03-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.